Risk factors for the development of depression in patients with hepatitis C taking interferon- α

: Interferon- α , currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However, not everyone who takes this drug becomes depressed, so it is important to understand what particular factors may make some individuals more ‘at risk’ of developing depression than others. Currently there is no consensus as to why interferon-induced depression occurs and the range of putative risk factors is wide and diverse. The identification of risk factors prior to treatment may allow identification of patients who will become depressed on interferon, allowing the possibility of improved treatment support and rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and we discuss the potential confounds within the research examined in order to better isolate the risk factors that may be important in the development of depression in these patients and which might help predict patients likely to become depressed on treatment. We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis C taking interferon- α .

[1]  G. Foster,et al.  Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection , 2010, Alimentary pharmacology & therapeutics.

[2]  B. Pollock,et al.  Labile Anger During Interferon Alfa Treatment is Associated With a Polymorphism in Tumor Necrosis Factor &agr; , 2010, Clinical neuropharmacology.

[3]  Daniel J Buysse,et al.  Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment , 2010, Psychiatry Research.

[4]  A. Miller,et al.  Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior , 2010, Molecular Psychiatry.

[5]  C. Pariante,et al.  Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon-α–Induced Depression by Regulating Polyunsaturated Fatty Acids Levels , 2010, Biological Psychiatry.

[6]  R. Fontana,et al.  A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. , 2010, Psychosomatics.

[7]  S. Hamilton,et al.  The genetics of major depression: moving beyond the monoamine hypothesis. , 2010, The Psychiatric clinics of North America.

[8]  B. Morasco,et al.  Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies , 2010, Neurobiology of Disease.

[9]  A. Hauschild,et al.  Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial , 2010, Journal of immunotherapy.

[10]  S. Abbey,et al.  A Review of Sleep Disturbance in Hepatitis C , 2010, Journal of clinical gastroenterology.

[11]  F. Lotrich Major depression during interferon-α treatment: vulnerability and prevention , 2009, Dialogues in Clinical Neuroscience.

[12]  M. Hotopf,et al.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment , 2009, Molecular Psychiatry.

[13]  B. Pollock,et al.  Cytokine-induced depression during IFN-α treatment: The role of IL-6 and sleep quality , 2009, Brain, Behavior, and Immunity.

[14]  R. Dantzer,et al.  CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.

[15]  R. Fontana,et al.  Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study , 2009, The American Journal of Gastroenterology.

[16]  R. Navinés,et al.  Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. , 2009, The Journal of clinical psychiatry.

[17]  D. F. Drake,et al.  Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression , 2009, Biological Psychiatry.

[18]  B. Pollock,et al.  Risk for Depression During Interferon-Alpha Treatment Is Affected by the Serotonin Transporter Polymorphism , 2009, Biological Psychiatry.

[19]  R. Fontana,et al.  Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C , 2008, The American Journal of Gastroenterology.

[20]  T. Harris,et al.  Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene-environment interaction. , 2008, Journal of affective disorders.

[21]  G. Pagnoni,et al.  IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C , 2008, Brain, Behavior, and Immunity.

[22]  M. J. van de Laar,et al.  Surveillance and epidemiology of hepatitis B and C in Europe - a review. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  N. Ozaki,et al.  A link between stress and depression: Shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression , 2008, Stress.

[24]  G. Foster,et al.  Hepatitis C virus therapy to date , 2008, Antiviral therapy.

[25]  M. Scheurlen,et al.  Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study , 2007, Gut.

[26]  H. Wittchen,et al.  Methodological approaches in the assessment of interferon‐alfa‐induced depression in patients with chronic hepatitis C – a critical review , 2007, International journal of methods in psychiatric research.

[27]  J. Russell,et al.  Neurobiology of depression: an integrated view of key findings , 2007, International journal of clinical practice.

[28]  M. Van Ranst,et al.  Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. , 2007, World journal of gastroenterology.

[29]  M. Miquel,et al.  De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C , 2007, Alimentary pharmacology & therapeutics.

[30]  P. Hauser,et al.  A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. , 2007, Journal of affective disorders.

[31]  R. Bressan,et al.  Incidence of psychiatric side effects during pegylated interferon‐ α retreatment in nonresponder hepatitis C virus‐infected patients , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[32]  B. Pollock,et al.  Depression following pegylated interferon-alpha: characteristics and vulnerability. , 2007, Journal of psychosomatic research.

[33]  B. Leonard HPA and Immune Axes in Stress: Involvement of the Serotonergic System , 2007, Neuroimmunomodulation.

[34]  R. Fontana,et al.  Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C , 2007, Hepatology.

[35]  J. Zajecka,et al.  Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C , 2007, Alimentary pharmacology & therapeutics.

[36]  K. Lesch,et al.  Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. , 2007, Gastroenterology.

[37]  M. Maj,et al.  Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. , 2007, Journal of psychosomatic research.

[38]  N. Nicolson,et al.  Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. , 2007, Journal of psychosomatic research.

[39]  V. de Lédinghen,et al.  Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C , 2006, Alimentary pharmacology & therapeutics.

[40]  D. Levinson The Genetics of Depression: A Review , 2006, Biological Psychiatry.

[41]  M. Maes,et al.  Baseline Immune Activation as a Risk Factor for the Onset of Depression During Interferon-Alpha Treatment , 2006, Biological Psychiatry.

[42]  J. McHutchison,et al.  Diagnosis and treatment of chronic hepatitis C infection , 2006, BMJ : British Medical Journal.

[43]  R. De La Garza,et al.  Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches , 2006, Journal of clinical gastroenterology.

[44]  Z. Younossi,et al.  Depression, anemia and health-related quality of life in chronic hepatitis C. , 2006, Journal of hepatology.

[45]  H. Anisman,et al.  The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity , 2005, Neuroscience.

[46]  A. Dunn,et al.  Cytokines as mediators of depression: What can we learn from animal studies? , 2005, Neuroscience & Biobehavioral Reviews.

[47]  N. Dafny,et al.  Interferon and the central nervous system. , 2005, European journal of pharmacology.

[48]  J. Korf,et al.  Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism , 2005, Psychosomatic medicine.

[49]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[50]  R. Hashimoto,et al.  The Gem interacting protein (GMIP) gene is associated with major depressive disorder , 2005, Neurogenetics.

[51]  Andrew H. Miller,et al.  Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings , 2005, Neuropsychobiology.

[52]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[53]  A. Heinz,et al.  Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. , 2005, Journal of hepatology.

[54]  D. Duane Increased risk for recurrent major depression in DYT1 dystonia mutation carriers , 2005, Neurology.

[55]  M. Rizzetto,et al.  Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. , 2005, Minerva gastroenterologica e dietologica.

[56]  H. Anisman,et al.  Cytokines as a precipitant of depressive illness: animal and human studies. , 2005, Current pharmaceutical design.

[57]  M. Wichers,et al.  Cytokines and major depression , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[58]  M. Rietschel,et al.  The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder , 2005, Biological Psychiatry.

[59]  M. Hotopf,et al.  Psychopathological symptoms during interferon-α and ribavirin treatment: effects on virologic response , 2005, Molecular Psychiatry.

[60]  C. Nemeroff,et al.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. , 2005, The Journal of clinical psychiatry.

[61]  Thomas Meitinger,et al.  Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment , 2004, Nature Genetics.

[62]  P. Hauser,et al.  The phenomenology and treatment of interferon-induced depression. , 2004, Journal of affective disorders.

[63]  Z. Younossi,et al.  Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. , 2004, Cleveland Clinic journal of medicine.

[64]  A. S. Elhwuegi Central monoamines and their role in major depression , 2004, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[65]  R. Dantzer,et al.  Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy , 2004, Brain, Behavior, and Immunity.

[66]  B. Bacon Managing hepatitis C. , 2004, The American journal of managed care.

[67]  Luca Mascitelli,et al.  Viral hepatitis C , 2004, The Lancet.

[68]  C. Nemeroff,et al.  Interferon-alpha–induced changes in tryptophan metabolism relationship to depression and paroxetine treatment , 2003, Biological Psychiatry.

[69]  Gustavo Turecki,et al.  Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.

[70]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[71]  C. Nemeroff,et al.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. , 2003, The American journal of psychiatry.

[72]  M. Scheurlen,et al.  Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. , 2003, The Journal of clinical psychiatry.

[73]  G. Davis,et al.  Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[74]  P. Thuras,et al.  A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. , 2003, Psychosomatics.

[75]  H. Grunze,et al.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.

[76]  B. Gohier,et al.  Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients , 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[77]  M. Maes,et al.  Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. , 2002, Journal of affective disorders.

[78]  D. Dhumeaux,et al.  Incidence of interferon alfa–induced depression in patients with chronic hepatitis C , 2002, Hepatology.

[79]  D. Revicki,et al.  Relationship of health‐related quality of life to treatment adherence and sustained response in chronic hepatitis C patients , 2002, Hepatology.

[80]  R. Dantzer,et al.  Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.

[81]  M. Maes,et al.  Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms , 2001, Psychiatry Research.

[82]  M. Scheurlen,et al.  Compliance with Therapy in Patients with Chronic Hepatitis C: Associations with Psychiatric Symptoms, Interpersonal Problems, and Mode of Acquisition , 2001, Digestive Diseases and Sciences.

[83]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[84]  B. van der Linden,et al.  Psychiatric comorbidity among hepatitis C-positive patients. , 2001, Psychosomatics.

[85]  Huy A. Nguyen,et al.  Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population , 2001, American Journal of Gastroenterology.

[86]  J. Eckman,et al.  Activation of Vascular Endothelial Cell Adhesion Molecule Expression by Sickle Blood Cells , 2001, Pediatric pathology & molecular medicine.

[87]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[88]  B. Redman,et al.  Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  M. Willenbring,et al.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. , 2000, The American journal of psychiatry.

[90]  Jensen,et al.  Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C , 2000, Journal of viral hepatitis.

[91]  R. Mulder,et al.  Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C , 2000, Journal of gastroenterology and hepatology.

[92]  H. Miyaoka,et al.  Depression from interferon therapy in patients with hepatitis C. , 1999, The American journal of psychiatry.

[93]  A. Ravaud,et al.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. , 1999, New England Journal of Medicine.

[94]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[95]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[96]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[97]  R. Dantzer,et al.  Molecular Basis of Sickness Behavior a , 1998, Annals of the New York Academy of Sciences.

[98]  K. Fukunishi,et al.  Burns in a suicide attempt related to psychiatric side effects of interferon. , 1998, Burns : journal of the International Society for Burn Injuries.

[99]  S. Donnelly Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. , 1998, Oncology nursing forum.

[100]  Mark E. Johnson,et al.  Hepatitis C virus and depression in drug users , 1998, American Journal of Gastroenterology.

[101]  M. Malaguarnera,et al.  Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha , 1998, Neuropsychobiology.

[102]  E. Schiff,et al.  Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial , 1996, Hepatology.

[103]  T. Okanoue,et al.  Side effects of high-dose interferon therapy for chronic hepatitis C. , 1996, Journal of hepatology.

[104]  C. Nemeroff,et al.  Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.

[105]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[106]  P. Brust,et al.  Peptides and blood-brain barrier transport. , 1993, Physiological reviews.

[107]  A. Dunn Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.

[108]  B. Hart Biological basis of the behavior of sick animals , 1988, Neuroscience & Biobehavioral Reviews.

[109]  J. Hoofnagle,et al.  Psychiatric complications of long-term interferon alfa therapy. , 1987, Archives of internal medicine.

[110]  H. Steinbusch,et al.  Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? , 2011, The international journal of neuropsychopharmacology.

[111]  Hymie Anisman,et al.  Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. , 2009, Journal of psychiatry & neuroscience : JPN.

[112]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[113]  S. Sauleda,et al.  The changing epidemiology of hepatitis C virus infection in Europe. , 2008, Journal of hepatology.

[114]  W. Yates,et al.  Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. , 2007, Digestive diseases and sciences.

[115]  S. Sleijfer,et al.  Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. , 2007, Neuropsychobiology.

[116]  C. Iino High dose interferon treatment in chronic hepatitis , 2006 .

[117]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[118]  MichaelRKraus,et al.  Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C , 2005 .

[119]  Andrew H. Miller,et al.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management. , 2005, CNS drugs.

[120]  E. D. De Toni,et al.  Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. , 2005, Journal of affective disorders.

[121]  K. Kowdley Hematologic side effects of interferon and ribavirin therapy. , 2005, Journal of clinical gastroenterology.

[122]  Andrew H. Miller,et al.  Cytokines and psychopathology: lessons from interferon-alpha. , 2004, Biological psychiatry.

[123]  C. Pariante,et al.  Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. , 2004, Journal of psychopharmacology.

[124]  Sergi Papiol,et al.  Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[125]  R. Dantzer,et al.  [Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression]. , 2003, Journal de la Societe de biologie.

[126]  N. Izumi,et al.  Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. , 2003, General hospital psychiatry.

[127]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[128]  M. Scheurlen,et al.  Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. , 2002, Alimentary pharmacology & therapeutics.

[129]  H. Meltzer,et al.  Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. , 2002, Journal of clinical psychopharmacology.

[130]  H. Grunze,et al.  Interferon alpha (IFNalpha) and psychiatric syndromes: a review. , 2002, Progress in neuro-psychopharmacology & biological psychiatry.

[131]  R. Fontana,et al.  Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. , 2002, Psychosomatics.

[132]  C. Howell,et al.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C , 2002, Molecular Psychiatry.

[133]  B. Charlton The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. , 2000, Medical hypotheses.

[134]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[135]  C. Pariante,et al.  Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. , 1999, Lancet.

[136]  S. Maier,et al.  Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.

[137]  W. Yates,et al.  Hepatitis C and depression , 1998, Depression and anxiety.

[138]  C. Hunt,et al.  Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. , 1997, Digestive diseases and sciences.

[139]  H. Janssen,et al.  Suicide associated with alfa-interferon therapy for chronic viral hepatitis. , 1994, Journal of hepatology.

[140]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.

[141]  S. Iino High dose interferon treatment in chronic hepatitis C. , 1993, Gut.

[142]  D. Begley Chapter 24: The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs , 1992 .